



Veeda Clinical Research has completed **18 oncology** patient based clinical studies so far, out of these **13** studies are PK endpoint studies and **4** phase II studies. We have enrolled more than 800 patients in oncology therapeutic area and worked with more than **100+ oncology** sites across India.

COMPLETED

**18**

ONCOLOGY  
STUDIES

PK ENDPOINT

**14**

STUDIES

PHASE II

**05**

STUDIES

WORKED WITH

**100+**

ONCOLOGY  
INVESTIGATORS

Below is the list of indications we worked in oncology therapeutic area along with number of patients enrolled in total.

## PATIENTS RECRUITED IN DIFFERENT ONCOLOGY INDICATIONS

### COMPLETED STUDIES

Indication	Number of Patients
Chronic Myeloid Leukemia (CML)	200
Metastatic Breast Cancer	124
Non-small Cell Lung Cancer (NSCLC)	119
Renal Cell Carcinoma (RCC)	88
Colorectal Cancer	48
Ovarian Cancer	38
Small Cell Lung Cancer (SCLC)	104

### ONGOING STUDIES

Indication	Number of Patients
Ovarian Cancer (three studies)	232
Metastatic Breast Cancer	86
Colorectal Cancer	20
Multiple myeloma	40

## REGULATORY INSPECTIONS

Veeda had successfully completed 15 FDA inspections at oncology investigator sites without any 483 observation.

### Investigators' Database

We have database of more than 125 Investigators' sites, directly worked with more than 100+ sites. For various oncology indications, we have evaluated detailed feasibility and having capabilities of enrolling patients with following indications with mentioned recruitment rate.

Indication	Number of Potential sites	General Recruitment rate per site per month
<b>Oncology: 117 sites</b>		
Ovarian Cancer (Advanced):	25 sites	1-2
Advanced or Metastatic Breast Cancer	20-25 sites	1-2
Multiple Myeloma	20-25 sites	0.5-1
Prostatic Carcinoma	15-20 sites	1-2
Chronic Myeloid Leukemia Chronic Phase	20-25 sites	3-4
Advanced Renal Cell Carcinoma	30 sites	0.5-0.75
Colorectal Cancer	30 sites	0.5-1
Small Cell Lung Cancer	20 sites	0.3-0.5
Non Small Cell Lung Cancer	25 site	1-1.5
Myelodysplastic Syndrome/AML	15-20 sites	0.5

### RARE INDICATIONS

# 1

Renal Cell Carcinoma: This is a challenging study due to very low incidence / rare patient population. Veeda had completed 2 studies within agreed timelines and budget for this indication.

# 2

Small Cell Lung Cancer : This is a very rare indication. Veeda had completed 1 phase-II global study & a PK study with 32 patients in total.

### Complex molecule - Liposomal Doxorubicin and protein bound paclitaxel

Veeda had completed the clinical study of Liposomal Doxorubicin and protein bound paclitaxel which is a challenging molecule in terms of PK processing at clinical sites. The said molecule is challenging in terms of buffer addition to the aliquots in very precise amount determines by plasma / serum separated from each sample.



Call us at  
+91 79 3001 3000



Mail us at  
info@veedacr.com



Visit us at  
www.veedacr.com

